Scarica l'app Stockscreener
16.48
2.69%
-0.455
Dopo l'orario di chiusura:
16.88
0.395
+2.40%
Precedente Chiudi:
$16.94
Aprire:
$16.85
Volume 24 ore:
670.26K
Relative Volume:
0.61
Capitalizzazione di mercato:
$904.48M
Reddito:
$14.34M
Utile/perdita netta:
$-199.00M
Rapporto P/E:
-4.2054
EPS:
-3.92
Flusso di cassa netto:
$-183.51M
1 W Prestazione:
-8.16%
1M Prestazione:
+15.28%
6M Prestazione:
+23.58%
1 anno Prestazione:
+197.56%
Intervallo 1D:
$16.48
$17.19
Intervallo di 1 settimana:
$16.48
$18.17
Portata 52W:
$4.45
$19.18
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
16.48 | 959.07M | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
Parkman Healthcare Partners LLC Sells 71,167 Shares of uniQure N.V. $QURE - MarketBeat
Huntington’s Disease Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Spark therapeutics, Chong Kun Dang Pharma, Neuvivo, UniQure Biopharma - Barchart.com
OMERS ADMINISTRATION Corp Takes $152,000 Position in uniQure N.V. $QURE - MarketBeat
Cubist Systematic Strategies LLC Makes New $2.56 Million Investment in uniQure N.V. $QURE - MarketBeat
uniQure (NASDAQ:QURE) Receives "Buy" Rating from Chardan Capital - MarketBeat
uniQure stock maintains Buy rating at H.C. Wainwright on promising Fabry data - Investing.com Nigeria
683 Capital Management LLC Boosts Stock Holdings in uniQure N.V. $QURE - MarketBeat
What does recent volatility data suggest for uniQure N.V.Market Growth Report & Real-Time Volume Analysis - Newser
Rafferty Asset Management LLC Invests $875,000 in uniQure N.V. $QURE - MarketBeat
uniQure reports positive initial data for Fabry disease gene therapy By Investing.com - Investing.com Nigeria
UniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data (NASDAQ:QURE) - Seeking Alpha
Chart based analysis of uniQure N.V. trendsCEO Change & Daily Entry Point Alerts - Newser
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing - GlobeNewswire
uniQure (QURE) Rating Reaffirmed with $70 Price Target by HC Wai - GuruFocus
uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease - Benzinga
UniQure Says Early Data for Fabry Disease Gene Therapy Shows Promise - MarketScreener
Long term hold vs stop loss in uniQure N.V.Weekly Trade Report & High Yield Equity Trading Tips - Newser
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease - The Manila Times
uniQure reports positive initial data for Fabry disease gene therapy - Investing.com
Is uniQure N.V. stock a top performer YTDJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - 더경남뉴스
Is uniQure N.V. exposed to political riskPortfolio Risk Summary & Smart Allocation Stock Reports - 더경남뉴스
uniQure N.V. stock chart pattern explainedJuly 2025 WrapUp & Community Trade Idea Sharing Platform - Newser
Using RSI to spot recovery in uniQure N.V.Index Update & Community Shared Stock Ideas - Newser
Rare Disease Therapy Approvals By FDA Speed Up Via New ProcessNeurogene (NASDAQ:NGNE) - Benzinga
Is uniQure N.V. stock overvalued or fairly pricedJuly 2025 Snapshot & Capital Efficient Trade Techniques - خودرو بانک
What indicators show strength in uniQure N.V.2025 Market Outlook & Free Risk Controlled Daily Trade Plans - Newser
Understanding uniQure N.V.’s price movementWeekly Earnings Recap & Low Drawdown Trading Techniques - Newser
What’s the RSI of uniQure N.V. stockJuly 2025 Movers & Low Risk Growth Stock Ideas - خودرو بانک
Visual analytics tools that track uniQure N.V. performanceQuarterly Portfolio Review & Weekly High Potential Alerts - Newser
Price action breakdown for uniQure N.V.2025 Valuation Update & High Conviction Buy Zone Alerts - Newser
What technical models suggest about uniQure N.V.’s comebackJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - Newser
Is now a turning point for uniQure N.V.Wall Street Watch & Weekly Top Stock Performers List - Newser
Has uniQure N.V. formed a bullish divergenceJuly 2025 Levels & Precise Buy Zone Identification - Newser
Will a bounce in uniQure N.V. offer an exitMarket Activity Summary & Daily Momentum Trading Reports - Newser
Relative strength of uniQure N.V. in sector analysisJuly 2025 Analyst Calls & Daily Technical Stock Forecast Reports - Newser
Ranking uniQure N.V. among high performing stocks via tools2025 Key Lessons & Consistent Growth Equity Picks - Newser
Can uniQure N.V. rally from current levelsJuly 2025 Price Swings & Accurate Buy Signal Alerts - Newser
Using economic indicators to assess uniQure N.V. potential2025 Historical Comparison & Smart Investment Allocation Tips - Newser
Should I hold or sell uniQure N.V. nowJuly 2025 Pullbacks & Real-Time Volume Spike Alerts - خودرو بانک
Can uniQure N.V. outperform in the next rallyJuly 2025 Update & Long-Term Safe Investment Ideas - خودرو بانک
Using data tools to time your uniQure N.V. exitPortfolio Profit Report & Weekly Stock Performance Updates - Newser
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Springhorn Jeremy P. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,694 |
| POST LEONARD E | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
29,937 |
| Kaye Jack | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
20,439 |
| Jacques Rachelle Suzanne | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
28,346 |
| Gut Robert | Director |
Jun 20 '25 |
Sale |
14.45 |
3,336 |
48,205 |
56,879 |
| Balachandran Madhavan | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,697 |
| Meek David D. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
34,190 |
| Potts Jeannette | Chief Legal Officer |
Jun 16 '25 |
Sale |
15.14 |
4,670 |
70,704 |
115,073 |
| Kapusta Matthew C | CEO, Managing Director |
Mar 04 '25 |
Sale |
10.29 |
28,341 |
291,629 |
651,454 |
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):